Immunotherapy · 2026
Utility of serum Krebs von den Lungen-6 and surfactant protein D levels for differential diagnosis of immune checkpoint inhibitor-related pneumonitis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakai Shogo, Karayama Masato, Inoue Yusuke, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Enomoto Noriyuki, Funayama Satoshi, Ichikawa Shintaro, Goshima Satoshi, Inui Naoki, Suda Takafumi
Аннотация
BACKGROUND: Serum Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) are established biomarkers of interstitial lung diseases. However, their utility for differential diagnosis of immune checkpoint inhibitor-related pneumonitis (ICI-P) remains unclear.
METHODS: This retrospective observational study included cancer patients who newly developed pulmonary diseases and in whom serum KL-6 and/or SP-D levels were measured at disease onset.
RESULTS: Among 200 eligible patients, 77 had ICI-P and 123 had other pulmonary diseases (bacterial pneumonia, n = 64; lymphangitic carcinomatosis, n = 42; pulmonary edema, n = 10; radiation pneumonitis, n = 5; and others, n = 2). Serum KL-6 and SP-D levels were significantly higher in patients with ICI-P than in those without (both p < 0.001). The area under the receiver operating characteristic curve was 0.684 for KL-6 and 0.771 for SP-D. KL-6 ≥500 U/mL showed sensitivity and specificity of 0.623 and 0.705, respectively, and SP-D ≥110 ng/mL showed sensitivity and specificity of 0.693 and 0.769, respectively. When both KL-6 ≥500 U/mL and SP-D ≥110 ng/mL, the sensitivity and specificity were 0.480 and 0.907, respectively.
CONCLUSIONS: KL-6 and SP-D may play a supportive role in the differential diagnosis of ICI-P.
METHODS: This retrospective observational study included cancer patients who newly developed pulmonary diseases and in whom serum KL-6 and/or SP-D levels were measured at disease onset.
RESULTS: Among 200 eligible patients, 77 had ICI-P and 123 had other pulmonary diseases (bacterial pneumonia, n = 64; lymphangitic carcinomatosis, n = 42; pulmonary edema, n = 10; radiation pneumonitis, n = 5; and others, n = 2). Serum KL-6 and SP-D levels were significantly higher in patients with ICI-P than in those without (both p < 0.001). The area under the receiver operating characteristic curve was 0.684 for KL-6 and 0.771 for SP-D. KL-6 ≥500 U/mL showed sensitivity and specificity of 0.623 and 0.705, respectively, and SP-D ≥110 ng/mL showed sensitivity and specificity of 0.693 and 0.769, respectively. When both KL-6 ≥500 U/mL and SP-D ≥110 ng/mL, the sensitivity and specificity were 0.480 and 0.907, respectively.
CONCLUSIONS: KL-6 and SP-D may play a supportive role in the differential diagnosis of ICI-P.